Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Postma, Maarten J ^a   Jit, Mark ^b   Rozenbaum, Mark H ^a   Standaert, Baudouin ^c   Tu, Hong Anh ^a   Hutubessy, Raymond C W ^d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; COMPARATIVE STUDY; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DESIGN; EPIDEMIOLOGY; HUMAN; IMMUNIZATION; INFECTION; INTERPERSONAL COMMUNICATION; LOWEST INCOME GROUP; MODEL; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; ROTAVIRUS INFECTION; SENSITIVITY ANALYSIS; STANDARDIZATION; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGY; METHODOLOGY; PREVENTIVE HEALTH SERVICE; REVIEW; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 79959921856     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-84     Document Type: Article

References (40)

1. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European Infants: randomized double-blind controlled study. Lancet 2007, 370:1757-1763. 10.1016/S0140-6736(07)61744-9, 18037080.
2. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33. 10.1056/NEJMoa052664, 16394299.
3. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22. 10.1056/NEJMoa052434, 16394298.
4. Jit M, Bilcke J, Mangen M-JJ, Salo H, Melliez H, Edmunds WJ, Yazdan Y, Beutels P. The Cost-effectiveness of Rotavirus Vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27:6121-6128. 10.1016/j.vaccine.2009.08.030, 19715781.
5. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007, 25:3971-3979. 10.1016/j.vaccine.2007.02.070, 17400341.
6. Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Prashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007, 119:684-697. 10.1542/peds.2006-2876, 17403839.
7. Bilcke J, Beutels P. Reviewing the cost-effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. PharmacoEconomics 2009, 27:281-297. 10.2165/00019053-200927040-00002, 19485425.
8. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health 2009, 9:29. 10.1186/1471-2458-9-29, 2663769, 19159483.
9. Wang XY, Riewpaiboon A, von Seidlein L, Chen XB, Kilgore PE, Ma JC, Qi SX, Zhang ZY, Hao ZY, Chen JC, Xu ZY. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis 2009, 49:1202-1210. 10.1086/605632, 19739973.
10. Tate JE, Rheingans RD, O'Reilly CE, Obonyo B, Burton DC, Tornheim JA, Adazu K, Jaron P, Ochieng B, Kerin T, Calhoun L, Hamel M, Laserson K, Breiman RF, Feikin DR, Mintz ED, Widdowson MA. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009, 200(Suppl 1):S76-S84.
11. De la Hoz F, Alvis N, Narvaez J, Cediel N. Potential epidemiological and economic impact of two rotavirus vaccines in Colombia. Vaccine 2010, 28:3856-3864. 10.1016/j.vaccine.2010.03.004, 20347057.
12. Tu HAT, Woerdenbag HJ, Kane S, Li SC, Postma MJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature
13. World Health Organization (WHO) Introduction of rotavirus vaccines into national immunization programmes 2009, Geneva: WHO, World Health Organization (WHO).
14. World Health Organization (WHO) World Health Report 2002 2002, Geneva: WHO, World Health Organization (WHO).
15. Jit M, Mangen MJJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, Edmunds WJ, Beutels P. An update to "The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe". Vaccine 2010, 28:7457-7459. 10.1016/j.vaccine.2010.08.060, 20846529.
16. Mangen MJJ, van Duynhoven YTHP, Vennema H, van Pelt W, Havelaar AH, de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?. Vaccine 2010, 28:2624-2635. 10.1016/j.vaccine.2010.01.014, 20109593.
17. GlaxoSmithKline (GSK) Roxanne internal report 2009, Wavre: GSK, GlaxoSmithKline (GSK).
18. Standaert B, Parez N, Tehard B, Detournay B. Cost-effectiveness Analysis of Vaccination against Rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008, 6:1-18. 10.2165/00148365-200806010-00001, 18774866.
19. Standaert B, Strens D, van Bellinghen LA, van Vlaenderen I. Comparing model predicted vaccine impact against Rotavirus hospitalization with observed data in Belgium. Value in Health 2010, 13:A444.
20. Goossens LMA, Standaert B, Hartwig N, Hövels AM, Al MJ. The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands. Vaccine 2008, 26:1118-1127. 10.1016/j.vaccine.2007.11.070, 18215445.
21. Rozenbaum MH, Mangen MJJ, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model.
22. Rozenbaum MH, Hak E, Wilschut JC, Postma MJ. Updating the cost-effectiveness of rotavirus vaccination in the Netherlands. Value in Health 2010, 13:A439A.
23. Huet F, Allaert FA, Trancart A, Miadi-Fargier H, Trichard M, Largeron N. Economic evaluation of acute paediatric rotavirus gastroenteritis in France. Archives de Pediatrie 2008, 15:1159-1166. 10.1016/j.arcped.2008.04.009, 18524550.
24. Brisson M, Senecal M, Drolet M, Mansi JA. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010, 29:73-75. 10.1097/INF.0b013e3181b41506, 19907361.
25. Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ 2008, 11:471-484. 10.3111/13696990802321047, 19450099.
26. United Nations United Nations., http://www.un.org
27. Mathers CD, Lopez AD, Murray CJL. The burden of disease and mortality by condition: Data, Methods and Results for 2001. Global burden of disease and risk factors 2006, 45-240. New York: Oxford University Press, Lopez A, Mathers C, Ezzati M, Jamison D, Murray CJL.
28. Murray CJ, Shengelia B, Gupta N, Moussavi S, Tandon A, Thieren M. Validity of reported vaccination coverage in 45 countries. Lancet 2003, 362:1022-1027. 10.1016/S0140-6736(03)14411-X, 14522532.
29. World Health Organisation (WHO) WHO-CHOICE: CHOosing Interventions that are Cost-Effective. 2008, Geneva: WHO, World Health Organisation (WHO)., http://www.who.int/choice
30. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, Murray C. Making choices in health: WHO guide to cost-effectiveness analysis 2003, Geneva: WHO.
31. International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Pharmacoeconomic guidelines over the world. 2011, Princeton (USA): ISPOR, International Society for Pharmacoeconomics & Outcomes Research (ISPOR)., http://www.ispor.org/peguidelines/index.asp
32. Milne RJ, Grimwood K. Should rotavirus vaccines be included in the national immunization program for a small developed country?. Expert Rev Pharmacoeconomics Outcomes Res 2009, 9:401-404.
33. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010, 201:1617-1624. 10.1086/652403, 20402596.
34. Van Effeltere T, Soriano-Gabarro M, Debrus S, Claire NE, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010, 138:884-897. 10.1017/S0950268809991245, 20028612.
35. Atchison C, Lopman B, Edmunds WJ. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010, 28:3118-3126. 10.1016/j.vaccine.2010.02.060, 20197142.
36. Brisson M, Edmunds WJ. Economic Evaluation of Vaccination Programs: the impact of herd immunity. Medical Decision Making 2003, 23:76-82. 10.1177/0272989X02239651, 12583457.
37. Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ 1997, 16:685-702. 10.1016/S0167-6296(97)00005-2, 10176779.
38. Chaiyakunapruk N, Somkrua R, Hutubessy R, Henao AM, Hombach J, Melegaro A, Edmunds JW, Beutels P. Cost-effectiveness of Pediatric Pneumococcal Conjugate Vaccines; a comparative assessment of decision making tools. BMC Med 2011, 9:53. 10.1186/1741-7015-9-53, 3117724, 21569402.
39. Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R. Human papillomavirus vaccine introduction in low and middle income countries; guidance on the use of cost-effectiveness models. BMC Med 2011, 9:54. 10.1186/1741-7015-9-54, 3123559, 21569406.
40. Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med 2011, 9:55. 10.1186/1741-7015-9-55, 3117725, 21569407.